Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

OBJECTIVES: More and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunotherapy is still a controversy for NSCLC patients...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Front Oncol
Main Authors: Chen, Ya, Yang, Zhengyu, Wang, Yanan, Hu, Minjuan, Zhang, Bo, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Han, Baohui
Formáid: Artigo
Teanga:Inglês
Foilsithe: Frontiers Media S.A. 2021
Ábhair:
Oncology
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085497/
https://ncbi.nlm.nih.gov/pubmed/33937084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.671228
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla